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INTRODUCTION
Central Serous Chorioretinopathy (CSCR) is a condition of unknown origin characterised by a serous detachment of the macula. It afflicts young healthy adults mostly men between the age of 20-50 years 1 . It is considered to occur secondary to a leak from the choriocapillaries through the Retinal Pigment Epithelium (RPE). 2 A recent study of choroidal perfusion suggests that choroidal ischemia might play a role in its pathogenesis.
Some patients also would develop into chronic CSCR with poor prognosis which is characterised by the widespread of distribution of small pigment epithelial detachments associated with areas of RPE atrophy and extensive pigmentary changes. 3, 4, 5 In rare cases, recurrent detachments and RPE changes can lead to permanent loss of vision. 4, 6 Bevacizumab (Avastin) is now approved by Food and Drug Administration (FDA) as an adjunct for the treatment of metastatic colorectal cancer and metastatic breast cancer in USA. 7 It is a monoclonal antibody that binds all iso-forms of Vascular Endothelial Growth Factor A (VEGF-A).
The use of Avastin to treat the patients with CSCR was accepted gradually recently. 8, 9, 10 However, the potential and uncertain risks and complication of intravitreal injection (IVI) were noted. 10, 11, 12 The main outcome included changes in stereopsis, contrast sensitivity, BCVA and CRT using OCT.
METHODS
Secondary outcome included any systemic or ocular adverse effects of injection and the need for repeated injections.
Statistical analysis was assessed using (SPSS-21 version). All variables were expressed as mean ± standard deviation (SD), the Wilcoxon sign rank test was used and p value <0.05 was considered statistically significant.
RESULTS
In this prospective study, 15 eyes of 15 patients In some cases, earlier intervention may be necessary due to high occupational demands for binocular vision. There are some studies in the literature supporting the benefit of early treatment of CSCR. These studies propose that the potential advantage of early resolution may be mediated by a lower rate of RPE degeneration in treated eyes. 15, 16 In some studies, the possible benefits of an anti-VEGF agent in CSCR were proposed on the basis of choroidal ischemia and hyperpermeability as pathogenethic mechanisms of CSCR. 17, 18, 19 Attempts to treat acute and chronic CSCR with intravitreal Bevacizumab are based on the hypothesis that choroidal hyperpermeability is associated with increased expression of VEGF. 20 Intravitreal Bevacizumab can terminate RPE leaking and prompt resolution of subretinal fluid, which can be associated with rapidly improving vision and remain stable. Although the exact mechanism of Bevacizumab in chronic CSC is unknown, it may be due to the effect of antimicrovascular permeability.
In our study all eyes had gained two or more lines improvement in BCVA at the end of follow up.
None of eyes had decreased vision than the baseline BCVA which was similar to the study done
by Mitzy E et al. 21 The mean baseline CRT for all patients was 533 o n e m o n t h a f t e r t r e a t m e n t ( i n t r a v i t r e a l Bevacizumab injection) and remained stable until the examination at the third month. 23 There were neither systemic nor intraocular adverse effects seen in our study except some sort of subconjunctival haemorrhage at the site of injection , which resolved spontaneously with time in three patients.
There were no cases of recurrence at the end of follow up. Small number of patients and lack of control group is the limitation of our study. However a large number of patients with longer follow up period are necessary to confirm the efficacy and safety of bevacizumab and determine the ideal protocol for this new promising treatment.
CONCLUSIONS

